MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…
MaaT PharmaJanuary 7, 2025
MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded…
MaaT PharmaDecember 5, 2024
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033…
MaaT PharmaNovember 26, 2024
MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting…
MaaT PharmaNovember 7, 2024
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes Completion…
MaaT PharmaNovember 5, 2024
MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute…
MaaT PharmaOctober 15, 2024
MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update Positive…
MaaT PharmaSeptember 19, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…
MaaT PharmaSeptember 9, 2024
MaaT Pharma To Present and Participate in Investor and Medical Conferences in September Lyon, France,…
MaaT PharmaSeptember 4, 2024
